Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $167.23M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.04M
Average 1.37M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$1.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Achieve Life Sciences, Inc. NASDAQ:ACHV | $697.68M | $6.78 | Not rated | -5.1 | +56.58% |
Puma Biotechnology, Inc. NASDAQ:PBYI | $401.70M | $7.77 | Overvalued | 15.4 | +41.11% |
Atea Pharmaceuticals, Inc. NASDAQ:AVIR | $345.31M | $4.30 | Not rated | -2.0 | +29.84% |
Editas Medicine, Inc. NASDAQ:EDIT | $334.92M | $2.17 | Not rated | -2.4 | -30.34% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $290.58M | $0.84 | Not rated | -2.7 | -43.20% |
Vanda Pharmaceuticals Inc. NASDAQ:VNDA | $241.27M | $3.99 | Not rated | -1.4 | -28.79% |
Entrada Therapeutics, Inc. NASDAQ:TRDA | $199.28M | $5.09 | Not rated | -1.7 | -43.76% |
Humacyte, Inc. NASDAQ:HUMA | $155.12M | $0.56 | Not rated | -1.9 | -58.25% |
Abeona Therapeutics Inc. NASDAQ:ABEO | $138.30M | $2.42 | Not rated | 4.9 | -41.96% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -64.49% |
Continue the stock analysis
Jump to another research area for this company.